Table 2 Univariable analysis of clinical and CMR characteristics for prediction of adverse events (N = 1342)
MACE | Cardiovascular Mortality | |||
|---|---|---|---|---|
Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value | |
Age | 1.02 (1.01–1.03) | 0.007 | 1.05 (1.03–1.07) | < 0.001 |
Male | 1.18 (0.80–1.73) | 0.400 | 1.28 (0.74–2.22) | 0.374 |
Body mass index | 0.96 (0.93–1.00) | 0.123 | 0.98 (0.93–1.01) | 0.382 |
Hypertension | 0.73 (0.55–0.97) | 0.031 | 0.74 (0.50–1.09) | 0.127 |
Diabetes mellitus | 0.91 (0.67–1.25) | 0.575 | 1.14 (0.75–1.71) | 0.546 |
Dyslipidemia | 0.89 (0.66–1.18) | 0.408 | 0.76 (0.51–1.12) | 0.168 |
Current or previous smoking | 1.09 (0.79–1.51) | 0.594 | 0.96 (0.61–1.52) | 0.861 |
Family history of CAD | 0.88 (0.64–1.19) | 0.401 | 1.04 (0.69–1.57) | 0.846 |
Prior PCI | 0.85 (0.64–1.13) | 0.263 | 0.56 (0.38–0.83) | 0.003 |
Prior CABG | 0.88 (0.64–1.19) | 0.401 | 1.04 (0.69–1.57) | 0.846 |
Stroke | 0.76 (0.28–2.05) | 0.592 | 0.74 (0.18–2.99) | 0.669 |
Renal Failure | 0.42 (0.06–3.00) | 0.387 | 0.00 (0.00– + ∞) | 0.993 |
Peripheral atheroma | 0.81 (0.47–1.39) | 0.442 | 1.01 (0.51–2.00) | 0.975 |
Heart failure hospitalization | 1.40 (0.62–3.15) | 0.422 | 1.84 (0.68–5.01) | 0.231 |
Presence of myocardial ischemia | 2.52 (1.90–3.34) | < 0.001 | 2.04 (1.38–3.03) | < 0.001 |
Number of segments of myocardial ischemia | 1.47 (1.39–1.56) | < 0.001 | 1.40 (1.29–1.53) | < 0.001 |
Presence of LGE | 1.66 (1.13–2.42) | 0.009 | 1.87 (1.08–3.24) | 0.025 |
Number of segments of LGE | 1.35 (1.26–1.45) | < 0.001 | 1.38 (1.25–1.53) | < 0.001 |
LVEF, per 10% | 0.84 (0.75–0.94) | 0.003 | 0.88 (0.75–1.03) | 0.101 |
LV end-diastolic volume index, per 10 ml/m2 | 1.06 (1.02–1.11) | 0.006 | 1.05 (0.98–1.11) | 0.150 |
LV end-systolic volume index, per 10 ml/m2 | 1.09 (1.03–1.14) | 0.001 | 1.07 (1.00–1.15) | 0.052 |
RV ejection fraction, % | 0.92 (0.75–1.15) | 0.490 | 1.05 (0.78–1.48) | 0.980 |